MLND Millendo Therapeutics Inc.

9.41
+0.43  (+5%)
Previous Close 8.98
Open 8.7
Price To Book 3.86
Market Cap 165,988,674
Shares 17,639,604
Volume 140,954
Short Ratio
Av. Daily Volume 84,933
Stock charts supplied by TradingView

NewsSee all news

  1. Millendo Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    Millendo Therapeutics, Inc. (NASDAQ:MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and

  2. Millendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer

    – Company also provides update on timeline for pivotal ZEPHYR study – Millendo Therapeutics, Inc. (NASDAQ:MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan

  3. Millendo Therapeutics Promotes Thomas Hoover to Chief Commercial Officer

    Millendo Therapeutics, Inc. (NASDAQ:MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today announced the

  4. Geoff Nichol Appointed to Millendo Therapeutics Board of Directors

    Millendo Therapeutics, Inc. (NASDAQ:MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today announced that

  5. Millendo Therapeutics Announces Pricing of Public Offering of Common Stock

    Millendo Therapeutics, Inc. (NASDAQ:MLND), a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced the pricing of its underwritten public offering of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data due early-2Q 2020.
Livoletide
Prader-Willi syndrome (PWS)
Phase 2b data due 2H 2020.
Nevanimibe
Congenital adrenal hyperplasia (CAH)

Latest News

  1. Millendo Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    Millendo Therapeutics, Inc. (NASDAQ:MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and

  2. Millendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer

    – Company also provides update on timeline for pivotal ZEPHYR study – Millendo Therapeutics, Inc. (NASDAQ:MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan

  3. Millendo Therapeutics Promotes Thomas Hoover to Chief Commercial Officer

    Millendo Therapeutics, Inc. (NASDAQ:MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today announced the

  4. Geoff Nichol Appointed to Millendo Therapeutics Board of Directors

    Millendo Therapeutics, Inc. (NASDAQ:MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today announced that

  5. Millendo Therapeutics Announces Pricing of Public Offering of Common Stock

    Millendo Therapeutics, Inc. (NASDAQ:MLND), a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced the pricing of its underwritten public offering of

  6. Millendo Therapeutics Announces Proposed Public Offering of Common Stock

    Millendo Therapeutics, Inc. (NASDAQ:MLND), a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced that it has commenced an underwritten public

  7. Millendo Therapeutics Reports Third Quarter 2019 Operating and Financial Results

    – Livoletide pivotal study in Prader-Willi syndrome (PWS) completed recruitment for patients ages 8 to 65 and is on track to report topline results in 1H20 – – Company to host PWS Breakfast Symposium on Thursday,

  8. Millendo Therapeutics Completes Patient Recruitment for Pivotal Study of Livoletide in Prader-Willi Syndrome

    – ZEPHYR study successfully recruits over 150 patients in eight months for Phase 2b portion of pivotal Phase 2b/3 study of livoletide in PWS patients ages 8 to 65 – – Recruitment will continue for a separate cohort of

  9. Millendo Therapeutics to Present at the Stifel 2019 Healthcare Conference

    Millendo Therapeutics, Inc. (NASDAQ:MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief

  10. Millendo Therapeutics to Host Prader-Willi Syndrome (PWS) Breakfast Symposium on Thursday, November 14, 2019

    – Prominent PWS clinical expert along with company management will discuss disease epidemiology, current treatment landscape and livoletide as a potential new therapy for PWS patients – – Live webcast to begin at 8:30

  11. Millendo Therapeutics to Present at Prader-Willi Syndrome Conferences

    Presentations on livoletide and PWS at the Foundation for Prader-Willi Research Annual Research Symposium and Family Conference and the Prader-Willi Syndrome Association USA National Convention Millendo Therapeutics,

  12. Millendo Therapeutics to Participate in September Investor Conferences

    Millendo Therapeutics, Inc. (NASDAQ:MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that senior management will present company overviews and